Puma Biotechnology (NASDAQ:PBYI) Stock Rating Reaffirmed by HC Wainwright

Puma Biotechnology (NASDAQ:PBYI)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They presently have a $7.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 44.03% from the stock’s current price.

Separately, StockNews.com cut Puma Biotechnology from a “buy” rating to a “hold” rating in a research note on Wednesday, April 10th.

Puma Biotechnology Trading Down 2.0 %

Shares of NASDAQ:PBYI traded down $0.10 during trading on Friday, reaching $4.86. 390,616 shares of the company were exchanged, compared to its average volume of 286,506. The company has a debt-to-equity ratio of 1.23, a current ratio of 1.57 and a quick ratio of 1.50. The firm has a market capitalization of $234.30 million, a PE ratio of 14.73, a P/E/G ratio of 2.77 and a beta of 1.31. The business’s fifty day simple moving average is $5.35 and its 200-day simple moving average is $4.67. Puma Biotechnology has a 12-month low of $2.13 and a 12-month high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.07). The business had revenue of $72.20 million during the quarter, compared to analysts’ expectations of $73.22 million. Puma Biotechnology had a return on equity of 37.69% and a net margin of 6.79%. On average, research analysts anticipate that Puma Biotechnology will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Great Point Partners LLC acquired a new stake in Puma Biotechnology in the fourth quarter worth about $4,734,000. Crestline Management LP raised its position in shares of Puma Biotechnology by 6.5% in the 4th quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 2,135 shares during the last quarter. Jump Financial LLC boosted its stake in Puma Biotechnology by 131.7% in the 4th quarter. Jump Financial LLC now owns 57,200 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 32,510 shares in the last quarter. Ritholtz Wealth Management purchased a new stake in Puma Biotechnology during the 4th quarter worth approximately $66,000. Finally, Assenagon Asset Management S.A. increased its stake in Puma Biotechnology by 23.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 85,039 shares of the biopharmaceutical company’s stock valued at $368,000 after purchasing an additional 15,897 shares in the last quarter. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.